(Total Views: 185)
Posted On: 09/27/2018 9:04:06 AM
Post# of 25416
$GNPX has signed an agreement with Aldevron to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex™ for the treatment of non-small cell lung cancer.
https://www.businesswire.com/news/home/20180927005155/en
https://www.businesswire.com/news/home/20180927005155/en
(0)
(0)Scroll down for more posts ▼
